Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · February 16, 2023

Front-Line Venetoclax and Rituximab for Young and Fit Patients With CLL and an Adverse Biologic Profile



Additional Info

Disclosure statements are available on the authors' profiles:

High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the gimema phase II LLC1518 - 'Veritas' study
Haematologica 2023 Jan 12;[EPub Ahead of Print], FR Mauro, ID Starza, M Messina, G Reda, L Trentin, M Coscia, P Sportoletti, L Orsucci, V Arena, GM Casaluci, R Marasca, R Murru, L Laurenti, F Ilariucci, C Stelitano, D Mannina, M Massaia, GM Rigolin, L Scarfò, M Marchetti, L Levato, M Tani, A Arcari, G Musuraca, M Deodato, P Galieni, VB Patrizi, D Gottardi, AM Liberati, A Giordano, MC Molinari, D Pietrasanta, V Mattiello, A Visentin, C Vitale, F Albano, A Neri, LA De Novi, MS De Propris, M Nanni, I Del Giudice, A Guarini, P Fazi, M Vignetti, A Piciocchi, A Cuneo, R Foà

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading